FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to a human bladder cancer cell line 587 BlCan TVV. Said line is used for preparing biomedical cell products, creating experimental models and testing anticancer preparations, expresses tumour-associated antigens NY-ESO-1, MAGEA1, BAGE, GAGE, HER-2new and stored in Specialized collection of vertebrate cell cultures of Russian collection of cell cultures under registration number RCCC (P) 792D.
EFFECT: invention allows extending the range of human tumour cell lines.
1 cl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMAN BLADDER CANCER CELL LINE 398 BLCAN KAE | 2020 |
|
RU2742245C1 |
| HUMAN BLADDER CANCER CELL LINE 190 BICAN KAG | 2021 |
|
RU2779948C1 |
| HUMAN BLADDER CANCER CELL LINE 198 BLCAN RLA | 2019 |
|
RU2733230C1 |
| HUMAN OVARIAN CANCER CELL LINE 533 OOS | 2017 |
|
RU2650759C1 |
| HUMAN ALVEOLAR SARCOMA CELL LINE 9927 AIS SIO | 2022 |
|
RU2796356C1 |
| APPLICATION OF CELL LINE OF RC291C CLEAR CELL ADENOCARCINOMA | 2018 |
|
RU2673729C1 |
| APPLICATION OF CELL LINE OF 369 ADMEL HUMAN SKIN MELANOMA | 2017 |
|
RU2642265C1 |
| APPLICATION OF HUMAN SKIN MELANOMA CELL LINE 388mel | 2018 |
|
RU2675541C1 |
| HUMAN EMBRYONIC RHABDOMYOSARCOMA CELL LINE 862 RMSAR KDD | 2020 |
|
RU2737248C1 |
| HUMAN COLORECTAL CANCER CELL LINE 485 COLO CAN | 2017 |
|
RU2650757C1 |
